E
Elizabeth H Barnes
Researcher at University of Sydney
Publications - 141
Citations - 12579
Elizabeth H Barnes is an academic researcher from University of Sydney. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 29, co-authored 116 publications receiving 9976 citations. Previous affiliations of Elizabeth H Barnes include Children's Hospital at Westmead & Royal Prince Alfred Hospital.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
Colin Baigent,L Blackwell,Jonathan Emberson,Lisa Holland,Christina Reith,Neeraj Bhala,Richard Peto,Elizabeth H Barnes,Anthony C Keech,John Simes,Rory Collins +10 more
TL;DR: Further reductions in LDL cholesterol safely produce definite further reductions in the incidence of heart attack, of revascularisation, and of ischaemic stroke, with each 1·0 mmol/L reduction reducing the annual rate of these major vascular events by just over a fifth.
Journal ArticleDOI
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials
Borislava Mihaylova,Jonathan Emberson,L Blackwell,Anthony C Keech,John Simes,Elizabeth H Barnes,Merryn Voysey,Alastair Gray,Rory Collins,Colin Baigent +9 more
TL;DR: Reduction of LDL cholesterol with a statin reduced the risk of major vascular events, largely irrespective of age, sex, baseline LDL cholesterol or previous vascular disease, and of vascular and all-cause mortality.
Journal ArticleDOI
Autism spectrum disorder
TL;DR: Using DSM-IV, patients could be diagnosed with four separate disorders: autistic disorder, Asperger's disorder, childhood disintegrative disorder, or the catch-all diagnosis of pervasive developmental disorder not otherwise specified as mentioned in this paper.
Journal ArticleDOI
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
Jane Armitage,Colin Baigent,Elizabeth H Barnes,D. John Betteridge,Lisa Blackwell,Michael A. Blazing,Louise Bowman,Eugene Braunwald,Robert P Byington,Christopher P. Cannon,Michael Clearfield,Helen M. Colhoun,Rory Collins,Björn Dahlöf,Kelly Davies,Barry R. Davis,James A. de Lemos,John R. Downs,Paul N. Durrington,Jonathan Emberson,Bengt Fellström,Marcus Flather,Ian Ford,Maria Grazia Franzosi,Jordan Fulcher,John H. Fuller,Curt D. Furberg,David L. Gordon,Shinya Goto,Antonio M. Gotto,Heather Halls,Charlie H.S. Harper,C. Morton Hawkins,William G. Herrington,Graham A. Hitman,Hallvard Holdaas,Lisa Holland,Alan G. Jardine,J. Wouter Jukema,John J.P. Kastelein,Sharon Kean,Anthony C Keech,Adrienne Kirby,John Kjekshus,Genell L. Knatterud,Robert H. Knopp,Wolfgang Koenig,Michael J. Koren,Vera Krane,Martin J Landray,John C. LaRosa,Eva Lonn,Peter W. Macfarlane,Stephen MacMahon,Aldo P. Maggioni,Roberto Marchioli,Ian C. Marschner,Borislava Mihaylova,Lemuel A. Moyé,Sabina A. Murphy,Haruo Nakamura,Andrew Neil,Connie B. Newman,Rachel O'Connell,Chris J. Packard,Sarah Parish,Terje R. Pedersen,Richard Peto,Marc A. Pfeffer,Neil Poulter,David Preiss,Christina Reith,Paul M. Ridker,Michele Robertson,Frank M. Sacks,Naveed Sattar,Roland E. Schmieder,Patrick W. Serruys,Peter S. Sever,John Shaw,Charles L. Shear,John Simes,Peter Sleight,Enti Spata,Luigi Tavazzi,Jonathan A. Tobert,Gianni Tognoni,Andrew Tonkin,Stella Trompet,John Varigos,Christoph Wanner,Hans Wedel,Harvey D. White,John Wikstrand,Lars Wilhelmsen,Kate Wilson,R. Young,Salim Yusuf,Faiez Zannad +98 more
TL;DR: A meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages observed a significant reduction in major vascular events in all age groups.
Journal ArticleDOI
Worm control and anthelmintic resistance: adventures with a model.
TL;DR: Elizabeth Barnes, Robert Dobson and Ian Barger examine some important factors that influence drug resistance and how farm management decisions and worm genetics modify these factors and the likely impact of new technologies on drug resistance.